Kuhl Jeanette, Sartipy Ulrik, Eliasson Björn, Nyström Thomas, Holzmann Martin J
Division of Cardiovascular Medicine, Danderyd University Hospital, Stockholm, Sweden; Department of Internal Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Sciences, Karolinska Institutet, Stockholm, Sweden.
Department of Cardiothoracic Surgery and Anaesthesiology, Karolinska University Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Int J Cardiol. 2016 Jan 1;202:291-6. doi: 10.1016/j.ijcard.2015.09.008. Epub 2015 Sep 12.
Patients with type 2 diabetes mellitus (T2DM) have an increased risk of coronary heart disease and death. We aimed to investigate the association between preoperative hemoglobin A1c (HbA1c) levels and long-term mortality after coronary artery bypass grafting (CABG) among patients with T2DM.
All patients with T2DM who underwent CABG in Sweden from 2003 to 2013 were included from the SWEDEHEART register. Information about diabetes was retrieved from the Swedish National Diabetes Register. We used Cox regression to calculate hazard ratios (HR) with 95% confidence intervals (CI) for all-cause mortality and also a combination of death or a major cardiovascular event (MACE).
In total, 6313 patients were included. During a mean follow-up time of 5.5 (±3.8) years, (34,482 person-years), 1630 (26%) patients died. After multivariable adjustment, HbA1c was associated with an increased risk of death in patients with HbA1c levels 9.1-10%, and >10% (HR (95% CI): 1.26 (1.04-1.53), and 1.33 (1.05-1.69), respectively). There was an increased risk for death or MACE at HbA1c levels 8.1-9%, 9.1-10%, and >10% (HR (95% CI): 1.17 (1.04-1.33), 1.44 (1.22-1.70), and 1.50 (1.22-1.84), respectively). In patients with insulin-treatment there was no association between HbA1c levels and death.
In patients with T2DM who underwent CABG we found an increased risk of death at HbA1c levels above 9.0%, and also for the combination of death or MACE at HbA1c levels above 8.1%. There was no association between HbA1c levels and death in T2DM patients who were insulin-treated.
2型糖尿病(T2DM)患者患冠心病和死亡的风险增加。我们旨在研究T2DM患者冠状动脉旁路移植术(CABG)术前糖化血红蛋白(HbA1c)水平与长期死亡率之间的关联。
从瑞典心脏注册研究(SWEDEHEART register)纳入2003年至2013年在瑞典接受CABG的所有T2DM患者。糖尿病信息从瑞典国家糖尿病注册中心获取。我们使用Cox回归计算全因死亡率以及死亡或主要心血管事件(MACE)组合的风险比(HR)及其95%置信区间(CI)。
总共纳入6313例患者。在平均随访时间5.5(±3.8)年(34482人年)期间,1630例(26%)患者死亡。多变量调整后,HbA1c水平在9.1 - 10%以及>10%的患者中,HbA1c与死亡风险增加相关(HR(95%CI):分别为1.26(1.04 - 1.53)和1.33(1.05 - 1.69))。HbA1c水平在8.1 - 9%、9.1 - 10%以及>10%时,死亡或MACE的风险增加(HR(95%CI):分别为1.17(1.04 - 1.33)、1.44(1.22 - 1.70)和1.50(1.22 - 1.84))。在接受胰岛素治疗的患者中,HbA1c水平与死亡之间无关联。
在接受CABG的T2DM患者中,我们发现HbA1c水平高于9.0%时死亡风险增加,HbA1c水平高于8.1%时死亡或MACE组合的风险增加。在接受胰岛素治疗的T2DM患者中,HbA1c水平与死亡之间无关联。